Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AL-3862+timolol · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| AL-3862+timolol, then COSOPT | OTHER | AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later. |
| COSOPT, then AL-3862+timolol | OTHER | Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later. |
| Name | Type | Description |
|---|---|---|
| AL-3862+timolol ophthalmic suspension | DRUG | - |
| Dorzolamide+timolol ophthalmic solution | DRUG | - |
Inclusion Criteria: * Sign informed consent; * Diagnosis of glaucoma or ocular hypertension; * On a stable regimen of any intraocular pressure (IOP) lowering medication (mono-therapy); * IOP for which, in the opinion of the investigator, participation in the study does not present a risk to ocular ...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
AL-3862+timolol is an investigational ophthalmic suspension being developed for glaucoma and ocular hypertension. It combines AL-3862 with timolol and is given as an eye drop. It is in Phase 3 clinical development and has not been approved by the FDA.
AL-3862+timolol is being developed by Alcon Inc., which trades on the New York Stock Exchange under the ticker ALC. Alcon is an eye care company, and this fixed combination product is part of its ophthalmology pipeline for lowering intraocular pressure in glaucoma.
AL-3862+timolol is in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The program has not been approved by the FDA and remains investigational for glaucoma and ocular hypertension.
AL-3862+timolol has been studied in one completed Phase 3 trial, NCT00576342, titled Patient Preference Study. It enrolled 129 participants aged 18 years and older with glaucoma or ocular hypertension. The trial was randomized, double blind, and controlled.